Page 92 - 《中国药科大学学报》2026年第1期
P. 92

86                        学报   Journal of China Pharmaceutical University 2026, 57(1): 78 − 89  第 57 卷
               A                              B                               C

                                    CA    1.5                      UDCA   1.0                     UDCA    1.0
                                    CDCA  1.0                      α-MCA                          α-MCA
                                    α-MCA  0.5                     β-MCA  0.5                     β-MCA   0.5
                                    β-MCA  0                       ω-MCA                          ω-MCA
                                    HDCA                           CA     0                       CA      0
                                    UDCA  −0.5                     CDCA                           CDCA
                                    ω-MCA  −1.0                    Tα-MCA  −0.5                   Tα-MCA  −0.5
                                    DCA   −1.5                     Tβ-MCA                         Tβ-MCA
                                    TCA                            TCA                            TCA
                                    TCDCA                          TCDCA                          TCDCA
                                    Tα-MCA                         GCDCA                          GCDCA
                                    GCA                            TDCA                           TDCA
                                    GCDCA                          TUDCA                          TUDCA
                                    Tβ-MCA                         GUDCA                          GUDCA
                                    GUDCA                          GCA                            GCA
                                    TDCA                           DCA                            DCA
                                    TUDCA                          HDCA                           HDCA
                                    GDCA                           TLCA                           TLCA
                                    TLCA                           GDCA                           GDCA
                Control Model 5-ASA CAPEC-H     IL-6  IL-1β TNF-α  NO          IL-6  IL-1β TNF-α iNOS
               Figure 6    Changes in bile acid concentrations (A) and Spearman’s correlations between bile acids and inflammatory factors in serum
               (B) and colon (C)
               Data were standardized by Z-scores, and the analyses were conducted using R software version 3.3.1. Colors red and blue represent positive and
               negative correlations respectively
               *P<0.05, **P<0.01
                  A

                      2.0        Control    Model     5-ASA     CAPEC-H         #
                     Relative mRNA expression  1.5  **  **  *  **  **  **          **  **          ns   *


                      1.0

                      0.5

                       0      ##              ##               ##                               ##
                              Cyp7a1          Cyp7b1          Cyp27a1          Cyp8b1            Bsep

                  B   2.0                       C    1.5                        D    6
                                         **                                                   ##
                   Relative mRNA level  of Fxr  1.0  #  *  Relative mRNA level  of Shp  1.0  **  **  Relative mRNA level  of Srebp-1  4 2  **  **
                      1.5



                                                     0.5
                      0.5

                       0                               0       ##                    0
                         Control  Model  5-ASA CAPEC-H   Control  Model  5-ASA CAPEC-H  Control  Model  5-ASA CAPEC-H



               Figure 7    Effects of CAPEC on FXR/SREBP-1 signaling pathway-related genes ( x ± s, n=5)
               #     ##
                P<0.05,  P<0.01 vs control group; *P<0.05, **P<0.01 vs model group
               Cyp7a1、Cyp7b1、Cyp27a1、Bsep mRNA     水平分别         (P<0.01)、5.6 倍(P<0.01)、4.6 倍(P<0.01)和   3.8 倍
               显著降低      57%(P<0.05)、86.3%(P<0.01)、85.9%        (P<0.05)。模型组     Srebp-1、Cyp8b1 mRNA   水平较
               (P<0.01)、84.6%(P<0.01)、87.2%(P<0.01)、和    82%    对照组分别升高        4.5 倍(P<0.01)和  1.5 倍(P<0.05),
               (P<0.01),与模型组相比,CAPEC-H          组分别使其升          CAPEC-H  组较模型组分别降低了             70.9%(P<0.01)
               高   2.5 倍 ( P<0.01) 、 5.6 倍 ( P<0.01) 、 5.5 倍    和  51.8%(P<0.01)。以上结果提示,CAPEC          能有效
   87   88   89   90   91   92   93   94   95   96   97